]>
IRCT20190916044781N1 IRCT 2019-10-13 Sarem Fertility and Infertility Research Center Use of the GnRh Agonist to Improve Outcome IVF Effect of GnRh Agonist short acting in IVF outcome improvement in FET cycles 2019-02-20 anticipated 240 Complete https://irct.ir/trial/42217 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: This study is an interventional type study (RCT) and it was designed to compare the effect of using short-acting GnRh agonist and not using it to improve IVF results in FET cycles. Simple randomization will be done by double-blind blocking and both the therapist and the statistician are not aware of the type of divisions. Patients are provided with informed consent forms after providing sufficient explanations about the study and it will be approved and signed by them. These patients will be emphasized and will be randomly divided into different treatment groups, Blinding description: The study will be double-blind and the therapist and the statistician are not aware of the type of segmentation. Patients entering FET cycle were randomly divided into control and intervention groups. N/A Condition 1: Infertility. Condition 2: Endometriosis preparation for freezing embryo transfer. Intervention 1: Intervention group: Twenty-one Cinafact units a day from progesterone onset will be given to the patient from Mid luteal phase and continue the same way and then from the second day of the period we are given 2-3 tablets of estrogen, ten days later the patient returns to the clinic And the endometrial thickness is measured And then progesterone is prescribed and the transfer is done. Intervention 2: Control group: In this group, we are administering 2-3 tablets daily of estrogen during the second day. 10 days later the patient is referred to the clinic and endometrial thickness is measured, If the endometrial thickness is above 8, the cycle will continue the same way and then progesterone is prescribed and the transfer is done. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is Observation of medical ethics and privacy and confidentiality of patients
public Dr. Farahnaz Zandi
Sarem Women's Hospital,Phase 3- Ekbatan Town, Tehran, iran
tehran Iran (Islamic Republic of) 1396956111 +98 21 4467 0883 dr.zandi@sarem.org Sarem Fertility and Infertility Research Center scientific Dr. Farahnaz Zandi
Sarem Women's Hospital,Phase 3- Ekbatan Town, Tehran, iran
tehran Iran (Islamic Republic of) 1396956111 +98 21 4467 0883 dr.zandi@sarem.org Sarem Fertility and Infertility Research Center Iran (Islamic Republic of) Have at least two embryos for transfer. The embryo has been removed from the freeze after thawing and has grade A quality. Absence of internal uterine anomalies such as adenomyosis and uterine fibroids and uterine malformations Absence of clear endometrioma Patients who used the agonist protocol in the ICSI cycle. Absence of systemic diseases (such as collagen, vascular disease, chronic hypertension, diabetes: a well-known case of diabetes with a fasting FBS of over 126) Vitamin D should be modified before starting ICSI. Age range from 25 to 40 years. 25 years 40 years Female Determine endometrioma during FET. N97 N98.9 Female infertility complication associated with artificial fertilization ,unspecified Treatment - Drugs Treatment - Drugs Intervention group: Twenty-one Cinafact units a day from progesterone onset will be given to the patient from Mid luteal phase and continue the same way and then from the second day of the period we are given 2-3 tablets of estrogen, ten days later the patient returns to the clinic And the endometrial thickness is measured And then progesterone is prescribed and the transfer is done. Control group: In this group, we are administering 2-3 tablets daily of estrogen during the second day. 10 days later the patient is referred to the clinic and endometrial thickness is measured, If the endometrial thickness is above 8, the cycle will continue the same way and then progesterone is prescribed and the transfer is done. Clinical pregnancy. Timepoint: Day 14 after transfer. Method of measurement: laboratory tests. Sarem Fertility and Infertility Research Center Approved 2019-02-03 Ethics Committee of Iran University of Medical Sciences Hemat Highway next to MMilad, Tehran,Iran. Tehran Tehran Iran (Islamic Republic of)